Overview

Trial of NanoPac Focal Therapy for Prostate Cancer

Status:
Terminated
Trial end date:
2021-02-08
Target enrollment:
Participant gender:
Summary
This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
NanOlogy, LLC
Collaborator:
US Biotest, Inc.
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel